Sai Parenterals Limited

Sai Parenterals Limited

Sai Parenterals Limited, an integrated CDMO and branded generics enterprise, has announced that its Australian subsidiary, Noumed Pharmaceuticals Pty Ltd, has renewed its OTC Medicines Supply Agreement with one of Australia's leading pharmacy chains. The renewal carries an expanded product portfolio, a long agreement tenure, and a higher agreement value, and is projected at AUD 30 million over a three-year term.

Sai Parenterals Limited

Sai Parenterals Limited has informed the Exchange about bagging/receiving of orders/contracts. The company's subsidiary Noumed Pharmaceuticals Pty Limited has renewed its long-term OTC Medicines Supply Agreement with one of Australia's leading pharmacy chains. The agreement is for a 3-year term with a projected value of AUD 30 Million, aggregating to approximately Rs. 204 Crores.

Sai Parenterals Limited

Sai Parenterals Limited has informed the Exchange about a scheduled Analyst/Institutional Investor Meeting on August 31, 2026, in Mumbai, where the management will interact with investors and discuss publicly available information.

Sai Parenterals Limited

Sai Parenterals Limited has announced the notice of its 25th Annual General Meeting (AGM) for the financial year 2025-26, to be held on September 10, 2026, through video conferencing.

Sai Parenterals Limited

Sai Parenterals Limited has submitted a copy of newspaper publication for a change and variation in the objects of utilization of the Initial Public Offering (IPO) proceeds.

Sai Parenterals Limited

Sai Parenterals Limited has informed the Exchange about Intimation of Book closure and cutoff date for the 25th Annual General Meeting.

Sai Parenterals Limited

Sai Parenterals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 10, 2026.

Sai Parenterals Limited

Sai Parenterals Limited has informed the Exchange about the transcript of the earnings conference call held on 12th August, 2026. The company's Q1 FY '27 earnings conference call was conducted on 12th August 2026 at 02:30 p.m. (IST). The transcript is available on the company's website and on the stock exchange's website. The company's consolidated total revenue for the quarter stood at Rs. 182 crores against Rs. 201 crores in the Q4 FY '26. Gross profit was Rs. 76 crores at a gross margin of 41.8%. EBITDA stood at Rs. 27 crores at a margin of 14.9% and profit after tax at Rs. 8 crores at a margin of 4.3%. The company's order flow has always been weighted towards the second half, with the 4th Quarter historically their strongest. Gross margin improved to 41.8% from 38.1% in the preceding quarter, an expansion of 370 basis points. The company has approved a proposed variation in the objects of the IPO issue, redeploying Rs. 101.85 crores originally earmarked for capacity expansion and upgradation of manufacturing facilities and research and development center.

Sai Parenterals Limited

Sai Parenterals Limited has informed the Exchange about the audio recording of the earnings call held on 12th August, 2026, available on their website.

Sai Parenterals Limited

Sai Parenterals Limited has made an investor presentation for its financial results for the quarter ended June 30, 2026, in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Sai Parenterals Limited

Sai Parenterals Limited has announced its un-audited financial results for the quarter ended 30.06.2026, with revenue of Rs. 182.4 crore, gross profit of Rs. 76.2 crore, EBITDA of Rs. 27.3 crore, and PAT of Rs. 7.9 crore. The company has also announced a proposed variation in the utilisation of IPO proceeds and a new critical-care injectable facility acquisition.

Sai Parenterals Limited

Sai Parenterals Limited has informed the Exchange about the resignation of a Director/KMP/SMP, but no further details are provided.

Sai Parenterals Limited

Sai Parenterals Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32, stating that there are no deviations or variations in the utilization of the proceeds of the Initial Public Offer (IPO) during the quarter ended June 30, 2026.

Sai Parenterals Limited

Sai Parenterals Limited has informed the Exchange about change in Management, with the Board Meeting approving the re-appointment of Mr. Anil Kumar Karusala as Director and Managing Director, and the appointment of Mr. Kunal Kakumanu as Additional and Executive Director. The meeting also approved the resignation of Ms. Shivali Aggarwal as Company Secretary & Compliance Officer and Mrs. Aruna Karusala as Non-Executive Director. Additionally, the company has announced the acquisition of a greenfield injectables manufacturing plant and an existing R&D facility, and the ratification of the Sai Parenterals Limited Employee Stock Option Plan, 2025.

Sai Parenterals Limited

Sai Parenterals Limited has submitted its un-audited financial results for the quarter ended June 30, 2026, and announced several board decisions, including the re-appointment of directors, acquisition of new facilities, and ratification of employee stock option plans.

Sai Parenterals Limited

Sai Parenterals Limited has scheduled an earnings conference call to discuss its operational and financial performance for the quarter ended June 30, 2026.

Sai Parenterals Limited

Sai Parenterals Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities for the quarter ended June 30, 2026.

Sai Parenterals Limited

Sai Parenterals Limited has informed the Exchange regarding the outcome of its Board Meeting held on July 06, 2026, where the Board approved the appointment of secretarial auditors, internal auditors, and cost auditors for the company.

Sai Parenterals Limited

Sai Parenterals' Australian subsidiary, Noumed Pharmaceuticals, has renewed its exclusive OTC supply agreement with a leading Australian pharmacy chain for a 7½-year term, valued at AUD 202 million (approximately INR 1300 crores).

Sai Parenterals Limited

Sai Parenterals Limited has informed the Exchange about bagging/receiving of orders/contracts. The company's subsidiary Noumed Pharmaceuticals Pty Limited has entered an OTC medicines supply agreement with Australia's leading pharmacy network valued at AUD 202 Millions (equivalent to INR 1300 crores). The agreement is for a period of 7.5 years with a further option of 3 years extension upon mutual consent.